Search

This momentousinvestment will serve as the catalyst for revolutionizing the landscape of living single cellanalysis.

Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal

At AseBio, we believe that it is crucial to reposition the biotechnology sector as a strategic industry. However, to achieve this, the collaboration of political and social efforts is essential.

The acquisition of aidhere strengthens Sidekick Health’s digital health offering to patients and partners with the world’s leading PDT company

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023).

During the 5th and 6th of October 2023, Granada hosted meetings of the European Political Community (EPC) and the heads of state or government of the EU, where the strategic priorities for the future

The operation was led by the Mind the Gap program from Botín Foundation, with participation from GENESIS Ventures and the Eurostars program.

The European Innovation Council (EIC) Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostic Accelerator (DxA) join the round, alongside other investors such as Lavanda Ventures, Ship2B

Meet ProductLife Group, our new partner. We spoke with Wendy Morales, business development manager.

Researchers at Nostrum Biodiscovery, with the collaboration of other companies, have laid the groundwork for the systematic development of optimal RNA-binding inhibitors based on antisense

Studies indicate that more than 60 percent of medication errors are caused by mistakes in interpersonal communication.

BCN HEALTH conducted a retrospective study based on the records of patients diagnosed with a melanoma and treated in Spanish public and private hospitals between January of 2011 and December of 2017.

BIOSPAIN 2023 brought together the global biotechnology industry in Barcelona and concluded its eleventh edition with record-breaking participation numbers. Over 2,100 attendees and more than 220

BIOSPAIN, the largest biotechnology event organised by a national bioindustry association in Europe, closed its XI edition in Barcelona on 28 September after three days of events with AseBio as

Two collaborative projects with public research centers with a global budget of 2.3 million euros.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give